









Markets
/
Stocks
/
nasdaq-elan
/

Elanco Animal Health Inc

ELAN

19.200USD

+0.110+0.58%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

9.54BMarket Cap

21.97P/E TTM



Elanco Animal Health Inc

19.200

+0.110+0.58%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

13 / 175

Overall Ranking

85 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 15 analysts

Buy

Current Rating

18.700

Target Price

-2.09%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Elanco Animal Health Incorporated is an animal health company. The Company is focused on delivering products and services to prevent and treat disease in farm animals and pets. Its diverse, durable product portfolio serves animals across many species, primarily: dogs, cats and cattle, poultry, swine, and sheep. It offers products in two primary categories: Pet Health and Farm Animal. Its Pet Health portfolio is focused on parasiticides, vaccines and therapeutics. Its Pet Health portfolio has products that protect pets from fleas, ticks and internal parasites. Its Farm Animal portfolio of products is primarily focused on cattle, swine, and poultry. Its Pet Health products include Advantage Family, Atopica, Claro/ Neptra, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its Farm Animal products include AviPro, Baycox, Catosal, Comforta, Denagard, Experior, Hemicell, Maxiban, Monteban, Pulmotil, Rumensin, and others.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD 338.00M.%!(EXTRA int=2)

Overvalued

The company’s latest PE is 21.87, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 515.44M shares, decreasing 7.31% quarter-over-quarter.

Held by Van Duyn Dodge & E. Morris Cox

Star Investor Van Duyn Dodge & E. Morris Cox holds 82.90M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.06.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 8.78, which is higher than the Pharmaceuticals industry's average of 7.84. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 1.24B, representing a year-over-year increase of 4.81%, while its net profit experienced a year-over-year increase of 122.00%.

Score

Industry at a Glance

Previous score

8.78

Change



Financials

6.24

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.67

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 1.80, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is 21.75, which is -14.79% below the recent high of 18.54 and 25.20% above the recent low of 16.27.

Score

Industry at a Glance

Previous score

1.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 13/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for Elanco Animal Health Inc is 19.00, with a high of 21.00 and a low of 16.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 15 analysts

Buy

Current Rating

18.700

Target Price

-2.60%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Elanco Animal Health Inc

ELAN

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 9.21, which is higher than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 19.87 and the support level at 17.72, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.21

Change

0.08

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-0.077

Neutral

RSI(14)

65.292

Neutral

STOCH(KDJ)(9,3,3)

84.904

Buy

ATR(14)

0.603

High Vlolatility

CCI(14)

116.431

Buy

Williams %R

3.016

Overbought

TRIX(12,20)

0.486

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

18.800

Buy

MA10

18.745

Buy

MA20

18.372

Buy

MA50

16.695

Buy

MA100

14.898

Buy

MA200

12.989

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 103.78%, representing a quarter-over-quarter increase of 0.80%. The largest institutional shareholder is Van Duyn Dodge & E. Morris Cox, holding a total of 82.90M shares, representing 16.69% of shares outstanding, with 0.84% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Dodge & Cox

Star Investors

82.92M

-0.31%

PRIMECAP Management Company

Star Investors

50.22M

-1.84%

Fidelity Management & Research Company LLC

38.30M

+34.35%

The Vanguard Group, Inc.

Star Investors

48.14M

-0.90%

Dimensional Fund Advisors, L.P.

20.46M

+14.32%

BlackRock Institutional Trust Company, N.A.

20.06M

-2.99%

T. Rowe Price Investment Management, Inc.

15.98M

+1.87%

Black Creek Investment Management, Inc.

22.04M

+7.87%

Fidelity Institutional Asset Management

15.55M

+32.70%

Citadel Advisors LLC

6.87M

+325.51%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.82, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 1.64. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.